A Benevolent Action
A partnership between Action Against AMD and BenevolentAI is helping to identify drugs for the treatment of AMD
Maryam Mahdi | | Quick Read
It is widely acknowledged that artificial intelligence (AI) is quickly becoming crucial for the future of ophthalmology. The ability of AI platforms to comb through large and often complex databases using big data analytics is also one that many pharmaceutical companies are keen to take advantage of for drug discovery. BeneloventAI is one of many AI companies drawing the attention of the industry; its AI platform makes sense of biomedical data via computational and experimental technologies, and the company has become well-recognized for its partnerships with key industry players.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.